Suzhou Alphamab Co. Ltd. is among the new generation of Chinese biopharmas moving rapidly along the evolutionary curve from contract research activities such as high-throughput screening, analytical biology and process development to the construction of a pipeline of biosimilars and, most recently, the development of novel compounds directed at cancer, autoimmune and infectious diseases.